10-K: ReShape Lifesciences Inc. Reports 2024 Results, Outlines Strategic Priorities Amidst Pending Merger and Asset Sale

ReShape Lifesciences Inc. details its 2024 financial performance and strategic initiatives, including a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International, while navigating challenges in the weight-loss market.

Summary

• ReShape Lifesciences Inc. reported its Form 10-K for the fiscal year ended December 31, 2024.
• The company is a physician-led weight-loss solutions provider with an integrated portfolio of products and services.
• Key products include the FDA-approved Lap-Band and Lap-Band 2.0 FLEX systems.
• In August 2022, Paul F. Hickey joined as President and CEO, pivoting the business strategy towards growth and profitability.
• The company focuses on three growth pillars: disciplined operations, product portfolio expansion, and evidence-based solutions.
• A 2024 cost reduction plan led to approximately 43% lower operating expenses compared to the previous year, excluding one-time costs.
• The Lap-Band 2.0 FLEX system received FDA approval in December 2023, with first surgeries completed in early 2024.
• A partnership with Biorad Medisys is expected to support the relaunch of the ReShape Obalon Balloon system in late 2025.
• The company remains committed to the Diabetes Bloc-Stim Neuromodulation (DBSN) technology, supported by $1.15 million in NIH grant funding.
• On February 25, 2025, an exclusive distribution agreement was signed with Liaison Medical Ltd. for the Lap-Band 2.0 FLEX system in Canada.
• On February 15, 2025, the company entered into a Security Purchase Agreement to issue and sell 2,575,107 shares of common stock and warrants.
• On February 3, 2025, a key international patent was granted from the State of Israel for its Diabetes Neuromodulation technology.
• An update on the definitive merger agreement with Vyome and the asset purchase agreement with Biorad Medisys was provided on January 13, 2025.
• An equity line of credit with Ascent Partners Fund LLC was established on December 19, 2024, for up to $5,000,000.
• A senior secured convertible note with Ascent was entered into on October 16, 2024, and repaid in full on February 18, 2025.
• A merger agreement with Vyome Therapeutics, Inc. and an asset purchase agreement with Ninjour Health International Limited were entered into on July 8, 2024.
• A 1-for-58 reverse stock split was effected on September 23, 2024.
• The company is developing and commercializing a differentiated portfolio of products/therapies.
• The company is driving the adoption of its portfolio through obesity therapy experts and patient ambassadors.
• The company is expanding and protecting its intellectual property position.
• The company believes its products and programs and product candidates could address a $1.64 billion per year and growing global surgical device market.
• The Bariatric Surgical Device market is projected to be a $2.8 billion worldwide market ($1.8 billion in the U.S.) by 2025.
• The Virtual Healthcare Delivery market is projected to be $95 billion worldwide by 2026.
• The Global Weight Loss and Obesity Management market is expected to rise to an estimated value of $300 billion with a compound annual growth rate of 6.7% from 2019 to 2026.
• Medical costs associated with obesity in the U.S. are estimated to be up to $210.0 billion per year.
• The company faces competition from bariatric laparoscopic and endoscopic procedures, and GLP-1 pharmaceuticals.
• The company relies on patents, trademarks, trade secret laws and confidentiality agreements to protect its intellectual property rights.
• The company markets directly to patients but sells the Lap-Band program to select qualified surgical centers.
• The company relies on third-party manufacturers and suppliers to produce its products.
• The company's products and operations are subject to extensive regulation by the FDA and other authorities.
• As of December 31, 2024, the company had 18 employees, of which 17 were full-time and 1 was part-time.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as new product approvals and strategic partnerships, the company faces challenges including declining revenue, ongoing losses, and the need for additional financing. The pending merger and asset sale add uncertainty.

Positives

• The Lap-Band 2.0 FLEX system received FDA approval in December 2023, with first surgeries completed in early 2024.
• A partnership with Biorad Medisys is expected to support the relaunch of the ReShape Obalon Balloon system in late 2025.
• The company remains committed to the Diabetes Bloc-Stim Neuromodulation (DBSN) technology, supported by $1.15 million in NIH grant funding.
• On February 25, 2025, an exclusive distribution agreement was signed with Liaison Medical Ltd. for the Lap-Band 2.0 FLEX system in Canada.
• On February 3, 2025, a key international patent was granted from the State of Israel for its Diabetes Neuromodulation technology.
• A 2024 cost reduction plan led to approximately 43% lower operating expenses compared to the previous year, excluding one-time costs.

Negatives

• Revenue totaled $8.0 million for the year ended December 31, 2024, which represents a contraction of 7.7%, or $0.7 million compared to the same period in 2023.
• The company has insufficient internal resources with appropriate accounting and finance knowledge and expertise to design, implement, document and operate effective internal controls around its financial reporting process.
• The company may not be able to raise capital to continue operations in the future which could result in bankruptcy or liquidation of the Combined Company.

Risks

• If the warrants issued in the February 2025 offering are exercised by way of a zero exercise price alternative, stockholders may suffer substantial dilution.
• The company may be unable to attract and retain management and other personnel it needs to succeed.
• The company may be unable to obtain required regulatory approvals for its DBSN device in a cost-effective manner or at all.
• The sale or issuance of the company's common stock to Ascent under its proposed equity line of credit transaction may cause dilution and the sale of the shares of common stock acquired by Ascent, or the perception that such sales may occur, could cause the price of the company's common stock to fall.
• The trading price of the company's common stock has been volatile and is likely to be volatile in the future.
• The company has a significant number of outstanding warrants, which may cause significant dilution to its stockholders, have a material adverse impact on the market price of its common stock and make it more difficult for it to raise funds through future equity offerings.
• The merger may not be consummated unless important conditions are satisfied or waived and there can be no assurance that the merger will be consummated.
• The company faces significant uncertainty in the industry due to government healthcare reform.
• The company is subject, directly or indirectly, to United States federal and state healthcare fraud and abuse and false claims laws and regulations.
• Failure to protect the company's information technology infrastructure against cyber-based attacks, network security breaches, service interruptions or data corruption could materially disrupt its operations and adversely affect its business.
• The company operates in a highly competitive industry that is subject to rapid change.
• The company's ability to use net operating losses (NOL) carryforwards may be limited.
• Adverse developments affecting the financial services industry could adversely affect the company's current and projected business operations and its financial condition and results of operations.

Future Outlook

The company anticipates closing the merger with Vyome and the asset sale in the second quarter of 2025, assuming the conditions to closing are satisfied. The combined company will focus on Vyome's business of advancing the development of its immuno-inflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market.

Management Comments

• Under this new leadership, our Company has pivoted its business strategy with the intent of helping to ensure growth and profitability.
• This first growth pillar remains, in our Companys opinion, paramount for ReShape to deliver shareholder value and, ultimately, profitability.

Industry Context

The company operates in the competitive obesity treatment market, facing competition from bariatric laparoscopic and endoscopic procedures, and GLP-1 pharmaceuticals. The company believes its products and programs and product candidates could address a $1.64 billion per year and growing global surgical device market.

Comparison to Industry Standards

• The Bariatric Surgical Device market is projected to be a $2.8 billion worldwide market ($1.8 billion in the U.S.) by 2025.
• The Virtual Healthcare Delivery market is projected to be $95 billion worldwide by 2026.
• The Global Weight Loss and Obesity Management market is expected to rise to an estimated value of $300 billion with a compound annual growth rate of 6.7% from 2019 to 2026.
• The company competes with Boston Scientific (ORBERA Intragastric Balloon System and OverStitch Endoscopic Suturing System) and Spatz Medical.
• The company competes with Novo Nordisk (Wegovy/Ozempic).

Legal Proceedings

• On December 2, 2024, the Company received a notice, dated November 22, 2024, from Rosenberg Law indicating that it is submitting an application to add the Company as a defendant in Canadian litigation (Raymond Edson Marshall v. Allergan Inc., Court File Reference VLC-S-S-151970) concerning the Lap-Band gastric banding device.

Stakeholder Impact

• The completion of the Merger and Asset Sale both remain subject to a number of conditions to closing, including the approval of its stockholders and, with respect to the Merger, the approval of the Nasdaq Stock Market, and there can be no assurance that the Merger and Asset Sale will be consummated.
• Failure to complete the Merger and Asset Sale could negatively impact its future operations, financial results and stock price.

Next Steps

• The company anticipates closing the merger with Vyome and the asset sale in the second quarter of 2025, assuming the conditions to closing are satisfied.
• The combined company will focus on Vyome's business of advancing the development of its immuno-inflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market.

Key Dates

Keywords

weight loss, obesity, Lap-Band, DBSN, Vyome, merger, Biorad, asset sale, financial results, medical devices